The Cardiology Channel

Actos vs Amaryl: Actos Reduces Atherosclerotic Progression

1:15 | Cardiology, Diabetes, Family Medicine, Internal Medicine, Nurses/NP/PA, Pharmacists, Preventative Health

New data stemming from the PERISCOPE trial show intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, Actos reduced the atherosclerotic burden in the coronary arteries compared to Amaryl, and prevented progression compared to baseline.

References and Resources
New data showed Actos prevented progression of atherosclerotic plaque volume in patients.

More in Cardiology

► 03:02

Repairing a Pediatric “Swiss Cheese Heart”

Cardiology

Cardiothoracic surgeon Dr. Emile Bacha describes and breaks down one of the most complicated cases of Swiss Cheese Septum seen at NewYork-Presbyterian Morgan Stanley Children's Hospital.

► 2:00:45

Athlete Respiratory Health

Cardiology

During the Athlete Respiratory Health session of the ISEH Annual Sports Cardio-Respiratory Medicine Conference, the speakers discussed respiratory health, the new IOC guideline on athlete respiratory health, how to protect...

► 02:00

The Cardiology Channel

Actos vs Amaryl: Actos Reduces Atherosclerotic Progression

More in Cardiology

Repairing a Pediatric “Swiss Cheese Heart”

Cardiology

Athlete Respiratory Health

Cardiology

Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Did Not Meet Noninferiority Compared to Coronary Artery Bypass Surgery

Cardiology

CHANGE AFib Clinical Trial Will Implement Early Intervention in Patients Diagnosed with Atrial Fibrillation

Cardiology